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Abstract. This study aimed to identify the potential key genes 
associated with severe pneumonia using mRNA-seq. Nine 
peripheral blood samples from patients with severe pneumonia 
alone (SP group, n=3) and severe pneumonia accompanied 
with chronic obstructive pulmonary disease (COPD; CSP 
group, n=3), as well as volunteers without pneumonia (control 
group, n=3) underwent mRNA-seq. Based on the sequencing 
data, differentially expressed genes (DEGs) were identified by 
Limma package. Following the pathway enrichment analysis 
of DEGs, the genes that were differentially expressed in the 
SP and CSP groups were selected for pathway enrichment 
analysis and coexpression analysis. In addition, potential genes 
related to pneumonia were identified based on the informa-
tion in the Comparative Toxicogenomics Database. In total, 
645 and 528 DEGs were identified in the SP and CSP groups, 
respectively, compared with the normal controls. Among 
these DEGs, 88 upregulated genes and 80 downregulated 
genes were common between the two groups. The functions 
of the common DEGs were similar to those of the DEGs in 
the SP group. In the coexpression network, the commonly 
downregulated genes (including ND1, ND3, ND4L, and ND6) 
and the commonly upregulated genes (including TSPY6P and 
CDY10P) exhibited a higher degree. In addition, 131 DEGs 
(including ND1, ND3, ND6, MIR449A and TAS2R43) were 
predicted to be potential pneumonia-related genes. In conclu-
sion, the present study demonstrated that the common DEGs 
may be associated with the progression of severe pneumonia.
Introduction
Pneumonia is defined as the inflammation and consolida-
tion of lung tissue due to an infectious agent. It is a leading 
cause of mortality worldwide, particularly in children and the 
elderly (1,2). Typical symptoms of pneumonia include fever, 
chills, pleuritic chest pain, and productive cough of purulent 
sputum (1). Severe pneumonia is defined as the admission 
to an intensive care unit (ICU) and results in extremely high 
mortality rates (3). Chronic obstructive pulmonary disease 
(COPD) is a major public health problem and is a leading 
cause of chronic morbidity and mortality worldwide (4). COPD 
is particularly prevalent in the elderly and it is a frequent 
comorbidity in patients with community-acquired pneumonia 
(CAP) (5). During treatment with corticosteroids in elderly 
patients with COPD, serious pneumonia typically occurs with 
a high risk (6,7). The severity of COPD, including the presence 
of pulmonary emphysema and the airflow limitation grade, 
has been demonstrated to be independently associated with 
the development of severe pneumonia (8). Furthermore, CAP 
patients with COPD have a similar mortality rate compared 
to those without COPD (9). Therefore, it is necessary to eluci-
date the molecular mechanism underlying severe pneumonia 
accompanied with COPD and compare it with the mechanism 
underlying severe pneumonia.
Several molecular mechanisms associated with severe 
pneumonia have been described. For instance, four risk 
single-nucleotide polymorphisms located in chromosomes 1 
and 17 have been identified as being significantly correlated 
with the susceptibility to developing severe pneumonia in 
A/H1N1 infection (10). Staphylococcal α-hemolysin is an 
essential virulence factor in severe Staphylococcus aureus 
pneumonia and α-hemolysin-mediated activation of the 
NLRP3 inflammasome may induce necrotic pulmonary 
injury (11). Furthermore, previous reports have indicated that 
severe pneumonia is associated with methicillin-resistant 
S. aureus carrying the staphylococcal cassette chromosome 
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mec type IV and Panton-Valentine leukocidin genes (12,13). 
Furthermore, a recent study reported that high expression of 
interleukin-10 (IL‑10) and interferon-induced protein (IP‑10) 
in human immunodeficiency virus-infected infants were 
associated with more severe hypoxic pneumonia (14). The 
IL‑6‑174 GG genotype is correlated with lower severity and 
mortality in patients with pneumococcal CAP (15). However, 
to date, there have been no studies reporting the molecular 
mechanisms underlying severe pneumonia accompanied with 
COPD, or comparing the similarities and differences between 
patients with severe pneumonia alone and severe pneumonia 
patients with COPD at the genetic level.
In the present study, mRNA-seq and bioinformatics were 
used to analyze the differential expression of genes in the 
peripheral blood from patients with severe pneumonia alone 
and severe pneumonia accompanied with COPD. Genes that 
were differentially expressed in the two groups of patients 
were analyzed. These findings may provide novel information 
for the understanding of the molecular mechanisms under-
lying severe pneumonia and severe pneumonia accompanied 
with COPD.
Materials and methods
Clinical samples. This study was approved by the Medical 
Ethics Committee of the Chinese People's Liberation Army 
(PLA) General Hospital (Beijing, China). In total, 18 patients 
with pneumonia who received therapy in Chinese PLA 
General Hospital between June 2013 and December 2013 were 
included in this study, including 9 patients with severe pneu-
monia alone (the SP group), 9 patients with severe pneumonia 
accompanied with COPD (the CSP group). Another 9 volun-
teers without pneumonia were enrolled as normal controls 
(the C group). For inclusion, patients with severe pneumonia 
met at least one of the following criteria: i) Disorders of 
consciousness; ii) respiratory rate ≥30/min; iii) diastolic blood 
pressure <60 mmHg, PaO2/FiO2 <300, and mechanical venti-
lation; iv) systolic blood pressure ≤90 mmHg; v) septic shock; 
vi) bilateral or multilobar pneumonia by chest radiograph, or 
lesions enlargement within 48 h after admission ≥50%; and 
vii) oliguria: urine volume <20 ml/h or <80 ml/4 h, or acute 
renal failure requiring dialysis treatment (16).
Peripheral blood samples were collected from each patient 
and volunteer. Written informed consent was obtained before 
sampling. In each group, three samples with an equal volume 
were randomly pooled into one sample for sequencing. 
Therefore, three sequencing samples were generated for each 
group: WLL1-3 for the SP group, WLL4-6 for the CSP group, 
and WLL7-9 for the C group.
RNA extraction and Illumina sequencing. Firstly, plasma 
was separated from the nine sequencing samples, respec-
tively. Total RNA was extracted and purified from the 
plasma samples using an miRNeasy Serum/Plasma Kit 
(Qiagen GmbH, Hilden, Germany). The quality control of 
RNA was measured using the Agilent Bioanalyzer 2100 
(Agilent Technologies, Inc., Palo Alto, CA, USA). The 
bioanalyzer software automatically generated the value of 
RNA Integrity Number (RIN, 1 to 10) based on the ratio 
of the 18S to 28S ribosomal subunits to determine the level 
of RNA degradation in gel electrophoresis, which removed 
individual interpretation in RNA quality control. RNAs 
with RIN ≥8.0 were used in the study. Subsequently, poly 
(A) mRNA was enriched by oligo (dT) magnetic beads 
(Dynabeads® oligo dT, Dynal Inc., Great Neck, NY), and 
then interrupted into shot fragments by fragmentation buffer 
(Agilent Technologies, Inc., Santa Clara, CA, USA). RNA 
fragments were then reverse transcribed into cDNA. The 
concentration of cDNA in the library was quantified into 
1 ng/µl with a Qubit 2.0 fluorometer, and then the cDNA 
were detected using the Agilent Bioanalyzer 2100 (Agilent 
Technologies, Inc.). Libraries were pooled according to the 
data size and effective cDNA concentration. Clusters of the 
cDNA libraries were generated on an Illumina cBot system 
(Illumina, Inc., San Diego, CA, USA). Finally, the cDNA 
libraries were sequenced using the rapid mode 2x150 bp 
paired-end reads on an Illumina HiSeq™ 4000 system 
(Illumina, Inc.). Raw sequencing data was uploaded to the 
public National Center for Biotechnology Information data-
base under the BioProject accession no. PRJNA325383.
Data filtering. Adapter sequences in the raw reads were 
removed using Cutadapt (version 1.2.1; cutadapt.readthedocs.
io/en/stable/) (17), with at least 10-bp overlap (AGATCGGAAG) 
and allowing for a 20% base error rate. Using a 5‑bp window, 
the mean quality value of each window was controlled to be 
at least 20. Shortening of the 3' terminal reads was permitted, 
although the shortest length was at least 50 bp. Reads with 
unknown sequences (‘N’) were removed.
Statistics and alignment of reads. The number of raw and 
clean reads, as well as the percentage of clean reads, was 
summarized to ensure the validity and reliability of the 
sequencing data. Furthermore, the index of the reference 
genome was created using Bowtie 2 (version 2.1.0; source-
forge.net/projects/bowtie-bio/files/bowtie2/2.1.0/), and clean 
reads were aligned to the human genome (hg19) using TopHat 
2.1.1 software (ccb.jhu.edu/software/tophat/index.shtml).
Differential expression analysis of genes. The read count 
of each gene was calculated by HTSeq 0.6.1p2 (huber.embl.
de/users/anders/HTSeq) and subsequently normalized 
using Trimmed Mean of M values normalization (18) in the 
Limma package (version 3.24.15; bioconductor.org/pack-
ages/release/bioc/html/limma.html). Normalized data were 
transformed to gene expression matrix using the voom 
method (19).
Subsequently, differentially expressed genes (DEGs) in the 
comparison groups of SP vs. C and CSP vs. C were identi-
fied using the edgeR package of Bioconductor (bioconductor.
org/packages/release/bioc/html/edgeR.html). Only the genes 
meeting the criteria of |log2 FC (fold change) |>1 and P<0.05 
were identified as DEGs.
Functional analysis of the DEGs. Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway enrichment 
analysis was performed for the identified DEGs using 
the clusterProfiler (version 2.2.7; bioconductor.org/pack-
ages/release/bioc/html/clusterProfiler.html) package of R (20). 
The P-value of each pathway term was calculated by Fisher's 
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exact test (21), and only the pathway terms with P<0.05 were 
considered significant.
Venn analysis of the DEGs. Gene symbols and their log2 FC 
values of the identified DEGs were input into the VennPlex 
software (version 1.0.02; irp.nia.nih.gov/bioinformatics/venn-
plex.html) (22) to compare the DEGs in the SP and CSP groups. 
Common upregulated and downregulated genes between the 
two groups were identified and defined as common DEGs.
Coexpression analysis of the common DEGs. Pearson correla-
tion coefficient (PCC) was used to screen the coexpression 
pairs among all of DEGs. P-value was calculated based on the 
Z-score of the coexpression pair, and |PCC| >0.9 and P<0.05 
were set as the cut-off criteria.
Furthermore, coexpression pairs of the common DEGs 
were selected for the construction of the coexpression network. 
Here, each pair must contain at least one common DEG. The 
network was visualized by Cytoscape 3.3.0 (cytoscape.org/). 
In the network, a ‘node’ represents a protein (or gene); a ‘line’ 
represents a coexpression pair of the proteins. The ‘degree’ of 
each node is equal to the number of nodes that coexpress with 
this node. The higher the degree is, the closer the connections 
with other nodes are, indicating a more important role of the 
node in the network.
Analysis of the potential pneumonia‑related genes. 
Comparative Toxicogenomics Database (CTD; ctdbase.
org/) provides manually curated information about 
chemical-gene/protein interactions, chemical-disease and 
gene-disease relationships (23). In this study, the keyword 
‘pneumonia’ was used to search the genes associated with 
pneumonia (April 26, 2016). The DEGs in the SP and CSP 
groups were then compared with the pneumonia-related genes 
in CTD using a venn tool (bioinformatics.lu/venn.php) in order 
to identify the potential pneumonia-related genes from the 
DEGs.
Results
Data summary of quality control and sequence alignment. 
Following quality control of the raw sequencing data, the 
percentage of clean data was >97% in the nine samples 
(Table I), indicating the sequencing data as of high quality. 
The sequence alignment of the clean reads to the hg19 indi-
cated that overall mapping rates in the majority of samples 
were between 60 and 75%. The concordant pair alignment rate 
was 50‑65% in the majority of samples (Table II).
Identification of DEGs. Based on the criteria, a total of 
645 DEGs (323 upregulated and 322 downregulated genes) 
were identified in the SP group, along with 528 DEGs 
(292 upregulated and 236 downregulated genes) in the CSP 
group, compared with the C group. These DEGs were able to 
distinguish the two group samples (Fig. 1A and B).
Pathway enrichment analysis of DEGs. To further investigate 
the potential biological functions of the identified DEGs, 
KEGG pathway enrichment analysis was performed. For the 
DEGs in the SP group, the upregulated gene HLA‑DRB5 was 
significantly enriched in the pathways associated with asthma, 
allograft rejection and intestinal immune network for IgA 
production, which were related to immunity. The downregu-
lated genes were mainly enriched in the pathways associated 
with aminoacyl-tRNA biosynthesis (TRNS1 and TRNM) and 
oxidative phosphorylation (COX3 and ND4L; Table III).
Furthermore, for the DEGs in the CSP group, the upregu-
lated genes (such as UGT2B17) were markedly enriched in 
the pathways of metabolism, including starch and sucrose 
metabolism, and ascorbate and aldarate metabolism. The 
downregulated genes were significantly enriched in the 
aminoacyl-tRNA biosynthesis (TRNS1 and TRNM) and oxida-
tive phosphorylation (COX3 and ND4L) pathways (Table IV), 
which is similar to those of the downregulated genes in the SP 
group.
Table I. Summary of the sequencing data after quality control.
Sample Raw data (Mb) Clean data (Mb) Percent (%)
WLL1 15857.06 15457.13 97.48
WLL2 30910.76 30140.40 97.51
WLL3 14380.84 13989.76 97.28
WLL7 16242.65 15811.34 97.34
WLL8 17571.73 17114.66 97.40
WLL9 12614.38 12283.53 97.38
WLL4 12177.13 11909.79 97.80
WLL5 21674.30 21182.59 97.73
WLL6 19091.95 18678.84 97.84
WLL1-3, samples from the patients with severe pneumonia alone; 
WLL4-6, samples from the severe pneumonia patients accompa-
nied with chronic obstructive pulmonary disease; WLL7-9, control 
samples. Percent=clean data/raw data.
Table II. Data summary of the sequence alignment.
 Left Right Overall Concordant
 mapped mapped mapping alignment pair
Sample reads reads rate (%) rate (%)
WLL1 40655723 31737852 68.50 53.20
WLL2 68307024 48549459 56.70 39.30
WLL3 36746057 28219712 67.80 52.80
WLL4 31492239 27325889 72.50 62.10
WLL5 57866494 49099958 74.00 62.30
WLL6 50706071 42750383 73.40 61.40
WLL7 38850721 28955703 62.60 46.50
WLL8 45900593 36937197 70.70 57.80
WLL9 32531013 25214426 68.70 55.00
WLL1-3, samples from the patients with severe pneumonia alone; 
WLL4-6, samples from the severe pneumonia patients accompa-
nied with chronic obstructive pulmonary disease; WLL7-9, control 
samples. Left mapped reads and right mapped reads represent the 
number of reads in both terminals that are mapped to the reference 
genome.
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Venn analysis of the DEGs and the functions of the common 
DEGs. To further investigate whether there are genes that are 
differentially expressed in the two pneumonia groups, the 
DEGs in the SP and CSP groups were compared. According 
to the venn diagram, 88 DEGs were upregulated in the two 
groups (named common-upregulated genes) and 80 were 
downregulated in the two groups (named common-downregu-
lated genes; Fig. 2A).
Furthermore, pathway enrichment analysis of the common 
DEGs revealed that the commonly upregulated gene, 
HLA‑DRB5, was significantly enriched in the pathways asso-
ciated with asthma, allograft rejection and intestinal immune 
network for IgA production. The commonly downregulated 
genes were enriched in the pathways aminoacyl-tRNA biosyn-
thesis (TRNS1 and TRNM) and oxidative phosphorylation 
(COX3 and ND4L) pathways (Fig. 2B). The functions of the 
common DEGs were similar to those of the DEGs in the SP 
group.
Analysis of the coexpression network. In total, 805 coex-
pression pairs of common genes were chosen to construct a 
network. The coexpression network consisted of 245 nodes and 
805 coexpression pairs. A series of 69 commonly upregulated 
genes and 65 commonly downregulated genes were included 
in the network (Fig. 3).
Some genes had a higher degree in the network, including 
ND3 (degree, 36), ND4L (degree, 36), TRNT (degree, 35), 
ND6 (degree, 35), TRNP (degree, 35), ATP8 (degree, 35), 
ND1 (degree, 35), MTND2P28 (degree, 35) and MTATP6P1 
(degree, 34). All of these genes were the commonly down-
regulated genes. Among the commonly upregulated genes, 
several genes exhibited high degrees, including TSPY6P 
(degree, 15), CDY10P (degree, 12), TTTY15 (degree, 11), 
RNA5SP233 (degree, 11), OFD1P3Y (degree, 9) and 
RN7SL255P (degree, 8; Fig. 3).
Identification of potential pneumonia‑related genes. Based 
on the information in CTD, 131 DEGs were identified to be 
associated with pneumonia, including 77 DEGs in the SP 
group and 54 DEGs in the CSP group (Table V). Among these 
DEGs, 4 commonly upregulated genes (MIR449A, TAS2R43, 
MIR656, and EIF5AP4) and 16 commonly downregulated 
genes (NOXO1, COX1, COX2, COX3, ND4, ND1, ND2, ND6, 
CYTB, ND3, SH3BGRL, ND5, ATP6, CPXCR1, VCX3B, and 
CT45A3) were included.
Discussion
In the present study, based on the mRNA-seq and bioinfor-
matics findings, a total of 645 and 528 DEGs were identified 
in the patients with severe pneumonia alone and severe pneu-
monia patients with COPD, respectively, compared with the 
normal controls. Among these DEGs, 88 upregulated genes 
and 80 downregulated genes were common between the 
two groups. In the coexpression network, the commonly 
downregulated genes (including ND1, ND3, ND4L, and ND6) 
and the commonly upregulated genes (including TSPY6P 
and CDY10P) had a higher degree. In addition, 131 DEGs 
(including COX1, COX2, COX3, ND1, ND3, and ND6) were 
predicted to be potential pneumonia-related genes.
ND1, ND3, ND4L and ND6 encode the subunits of NADH 
dehydrogenase, which participate in the mitochondrial oxida-
tive phosphorylation, functioning in the transfer of electrons 
from NADH to the respiratory chain (24). A previous study 
has demonstrated that the type I NADH dehydrogenase of the 
human pathogen Mycobacterium tuberculosis (Mtb) is able 
to neutralize NOX2-derived reactive oxygen species to inhibit 
tumor necrosis factor-α-mediated host macrophage apoptosis 
in innate immunity (25). Differentially expressed NADH 
dehydrogenase subunits were detected during the immune 
response of Ostrea edulis against bonamiosis (26). These 
results indicate the association of NADH dehydrogenase with 
immunity, which is an essential factor in the progression of 
Figure 1. Heat maps of the DEGs. (A) Heat map of DEGs between the severe 
pneumonia alone group and the control group. (B) Heat map of DEGs between 
the severe pneumonia with COPD group and the control group. Green indi-
cates downregulated and red indicates upregulated. DEGs, differentially 
expressed genes; COPD, chronic obstructive pulmonary disease. WLL1-3, 
samples taken from patients with severe pneumonia alone; WLL4-6, samples 
taken from severe pneumonia patients accompanied with COPD; WLL7-9, 
samples taken from the normal controls.
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pneumonia. In the present study, ND1, ND3 and ND6 were 
identified as potential pneumonia‑related genes. Therefore, 
these genes encoding NADH dehydrogenase subunits may 
have crucial roles in the progression of severe pneumonia.
Table III. Enriched pathway terms of differentially expressed genes in the patients with severe pneumonia alone compared with 
the controls.
Pathway ID Description P-value Genes
Upregulated
  hsa05310 Asthma 3.12E-02 HLA‑DRB5
  hsa05330 Allograft rejection 3.91E-02 HLA‑DRB5
  hsa05332 Graft-versus-host disease 4.30E-02 HLA‑DRB5
  hsa04940 Type I diabetes mellitus 4.50E-02 HLA‑DRB5
  hsa04672 Intestinal immune network 4.89E-02 HLA‑DRB5
 for IgA production
Downregulated
  hsa00970 Aminoacyl-tRNA biosynthesis 1.18E-30 TRNS1, TRNM, TRNW, TRNG, TRNH, TRNL1, TRNN,
   TRNC, TRNA, TRNP, TRNE, TRNT, TRNV, TRNS2, TRND,
   TRNI, TRNQ, TRNK, TRNY, TRNL2, TRNF, TRNR
  hsa05012 Parkinson's disease 1.35E-10 COX3, ND4L, COX2, ND1, COX1, ND4, ATP8,
   CYTB, ND3, ND5, ND2, ATP6, ND6
  hsa00190 Oxidative phosphorylation 1.64E-10 COX3, ND4L, COX2, ND1, COX1, ND4, ATP8,
   CYTB, ND3, ND5, ND2, ATP6, ND6
  hsa05016 Huntington's disease 1.59E-03 GPX1, COX3, COX2, COX1, ATP8, CYTB, ATP6
  hsa05010 Alzheimer's disease 4.89E-03 COX3, COX2, COX1, ATP8, CYTB, ATP6
  hsa04260 Cardiac muscle contraction 5.92E-03 COX3, COX2, COX1, CYTB
Table IV. Enriched pathway terms of differentially expressed genes in the severe pneumonia patients accompanied with chronic 
obstructive pulmonary disease compared with the controls.
Pathway ID Description P-value Genes
Upregulated
  hsa00500 Starch and sucrose metabolism 2.23E-03 UGT2B17, AMY1C
  hsa00980 Metabolism of xenobiotics 3.82E-03 UGT2B17, GSTM1
 by cytochrome P450
  hsa00982 Drug metabolism-cytochrome P450 4.04E-03 UGT2B17, GSTM1
  hsa00053 Ascorbate and aldarate metabolism 3.48E-02 UGT2B17
  hsa05310 Asthma 4.13E-02 HLA‑DRB5
  hsa00040 Pentose and glucuronate interconversions 4.26E-02 UGT2B17
Downregulated
  hsa00970 Aminoacyl-tRNA biosynthesis 5.87E-36 TRNL1, TRNS2, TRNR, TRNV, TRNH, TRNC,
   TRNN, TRNP, TRNY, TRNT, TRNG, TRNE, TRNQ, 
   TRNI, TRNF, TRNS1, TRNW, TRNA, TRND,
   TRNK, TRNL2, TRNM
  hsa05012 Parkinson's disease 3.63E-13 COX1, COX2, COX3, ND1, ATP6, ND4L, ND4,
   ATP8, ND3, ND2, CYTB, ND5, ND6
  hsa00190 Oxidative phosphorylation 4.43E-13 COX1, COX2, COX3, ND1, ATP6, ND4L, ND4,
   ATP8, ND3, ND2, CYTB, ND5, ND6
  hsa05010 Alzheimer's disease 5.47E-04 COX1, COX2, COX3, ATP6, ATP8, CYTB
  hsa05016 Huntington's disease 8.60E-04 COX1, COX2, COX3, ATP6, ATP8, CYTB
  hsa04260 Cardiac muscle contraction 1.28E-03 COX1, COX2, COX3, CYTB
  hsa01100 Metabolic pathways 1.63E-02 COX1, COX2, COX3, ND1, ATP6, ND4L, ND4,
   ATP8, ND3, ND2, CYTB, ND5, ND6
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Commonly downregulated genes, COX1, COX2 and COX3, 
were also predicted as potential pneumonia-related genes. 
These three genes all encode isoforms of cyclooxygenase, 
which has a critical role in various normal physiological func-
tions and regulates a variety of pathological conditions (27). 
Previous studies have demonstrated the associations of COX2 
with inflammation and immunity (27,28). In the immune 
response of pneumonia, COX2 expression is induced in lung 
lesions (27,29,30), which is inconsistent with the result of 
the current study. This disparity may be due to the differ-
ence of sample types used for COX2 detection. In our future 
studies, COX2 expression will be determined in lung tissue 
and peripheral blood of patients with severe pneumonia and 
normal control subjects.
With the exception of the downregulated genes, several 
commonly upregulated genes also had a higher degree in 
the coexpression network, including TSPY6P and CDY10P, 
which are pseudogenes. In recent years, the biological 
Figure 2. Venn diagram (A) and results of pathway enrichment analysis (B) for the differentially expressed genes. SP, severe pneumonia; CSP, severe pneu-
monia with chronic obstructive pulmonary disease; C, control; Up, upregulated genes; Down, downregulated genes.
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Figure 3. Coexpression network of the differentially expressed genes. White nodes represent the upregulated genes and grey nodes represent the downregu-
lated genes. Round nodes represent the genes that are differentially expressed only in the patients with severe pneumonia alone. Quadrate nodes represent the 
genes that are differentially expressed only in the severe pneumonia patients with chronic obstructive pulmonary disease. Triangular nodes represent the genes 
that are differentially expressed in both patients with severe pneumonia alone and severe pneumonia patients with chronic obstructive pulmonary disease. The 
solid line represents the positive correlation, namely, the Pearson correlation coefficient >0; the dotted line represents the negative correlation, namely, the 
Pearson correlation coefficient <0.
Table V. Potential pneumonia‑related genes identified from the differentially expressed genes based on the Comparative 
Toxicogenomics Database.
Category Potential pneumonia-related genes
Severe pneumonia alone group PF4, TIMP1, GPX1, B2M, FTH1, NOXO1, PPBP, SDPR, TMSB4X, COX1, PCBP1,
 SH3BGRL3, NRGN, COX2, LRRC26, RGS18, FLNA, ITGB3, TCEAL7, SAA4, ACOT1,
 HAPLN4, COX3, ND4, HBA1, HLA‑E, HIST1H2AH, ND1, PGRMC1, TUBB, ND2,
 RPL15, MIR148B, ND6, MIR205, CYTB, APOBEC3B, ND3, PCDH20, MIR449A,
 SH3BGRL, HLA‑DRB5, USP17L9P, ND5, MIR193A, HBA2, SNORA12, MIR559,
 MIR572, TAS2R43, CSNK2B, SPANXB1, SLX1A, FTHL17, LY6G6E, SLC10A3,
 MIR339, RNR1, MIR513B, HLA‑DRB6, MIR4300, MIR656, ATP6, POTEF, CPXCR1,
 RN7SK, FAM138A, RPS18P9, SNORD115‑30, MIR873, MIR190A, RBMY2EP, RNU1‑1,
 EIF5AP4, VCX3B, MIR4499, CT45A3
Severe pneumonia accompanied GSTM1, JUND, NOXO1, COX1, COX2, COX3, MRPL12, ND4, ND1, SPANXD, ND2,
with chronic obstructive RPS20, ND6, CYTB, MDP1, ND3, EIF4EBP3, MIR93, HNRNPU, MIR449A, MIR100,
pulmonary disease group SH3BGRL, RPS4Y2, HLA‑DRB5, IGKV1‑17, ND5, UGT2B17, TAS2R43, MT1P3,
 POM121L8P, MIR188, LCE3C, GLOD5, CYB5D1, HBG1, MED14OS, INSL5, MIR656,
 SNORD113‑3, ATP6, DTX2P1‑UPK3BP1‑PMS2P11, CPXCR1, DUX4L4, SNORA28,
 MIR190A, F8A3, MIR19B2, OR7E125P, EIF5AP4, MIR216A, VCX3B, TRBV21‑1,
 RNU4‑2, CT45A3
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functions of pseudogenes have been increasingly investi-
gated, and pseudogenes have been reported to serve a role 
in formation of tumors (31). However, to the best of our 
knowledge, there have been no reports on the functions of 
TSPY6P and CDY10P. Therefore, the present study was the 
first to demonstrate TSPY6P and CDY10P were deregulated 
in patients with severe pneumonia, and were thus worthy of 
further research.
Furthermore, in this study, 4 commonly upregulated 
genes (MIR449A, TAS2R43, MIR656 and EIF5AP4) were 
identified as potential pneumonia‑related genes. MIR449A 
and MIR656 encode miR-449a and miR-656, respectively. A 
previous study has demonstrated that miRNA-449a modu-
lates the expression of the inflammatory marker, YKL40, 
by targeting components of the NOTCH signaling pathway, 
indicating the important role of miR‑449a in the inflamma-
tory response (32). TAS2R43 encodes taste 2 receptor member 
43, which belongs to the large TAS2R receptor family. An 
agonist for TAS2R1 and other TAS2Rs, amarogentin, is able 
to decrease IL‑8 and MMP‑1 expression in mast cells (33), 
suggesting the potential association of TAS2R43 with 
immunity. Therefore, MIR449A and TAS2R43 may have a 
critical role in the progression of severe pneumonia, possibly 
via participating in inflammation and immunity. However, 
MIR656 and EIF5AP4 have not yet been reported to be 
related to pneumonia, thus, they are novel genes that are 
potentially associated with severe pneumonia.
Although a set of upregulated and downregulated genes 
were common in the samples from patients with severe pneu-
monia alone and patients with severe pneumonia accompanied 
with COPD, there were a series of genes that were differen-
tially expressed between the two patient groups according to 
the venn diagram analysis performed in the present study. The 
differences in molecular mechanisms between severe pneu-
monia and severe pneumonia accompanied with COPD will 
be further investigated in our future studies.
In conclusion, the downregulated genes encoding NADH 
dehydrogenase subunits (ND1, ND3, ND4L and ND6) and the 
upregulated genes (TSPY6P, CDY10P, MIR449A, TAS2R43, 
MIR656, and EIF5AP4) are newly‑identified genes that may 
be associated with the progression of severe pneumonia. These 
genes will be further researched in our future studies. These 
results provide novel information for further experimental 
studies to build upon and contribute to the continued under-
standing of the molecular mechanisms underlying severe 
pneumonia.
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